Interactive pipeline

 APP   04/2021

We are advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. We have three internally-developed late-stage clinical drug candidates, four marketed products in China and one marketed product in the U.S.

Explore our interactive pipeline to discover our extensive clinical portfolio, spanning a broad range of solid tumor and hematological malignancy indications. Find out more about our drugs and clinical trials in your target indications.


Rate this resource

Nice to see you!

For newest details on our EHA materials in a personal video meeting, please click here!